atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
15 mai 2024 06h59 HE
|
atai Life Sciences
First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H’24; Phase 2 study in TRD patients anticipated to initiate around YE’24Beckley Psytech’s Phase 2a study of BPL-003 in TRD...
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
14 mai 2024 08h00 HE
|
Optimi Health Corp.
Optimi Health Receives Certificate of Analysis For GMP MDMA 40mg and 60mg MDMA Capsules.
Optimi Health Provides Corporate Update
10 mai 2024 08h50 HE
|
Optimi Health Corp.
Optimi Health provides corporate update.
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research
09 mai 2024 08h00 HE
|
Optimi Health Corp.
Export Permit granted: Optimi's Shipment of MDMA active pharmaceutical ingredient (API) to Israel marks the Company’s first international export
Dr. Richard Goldberg Joins Real Brands' Board of Directors, Enters Consulting Agreement
07 mai 2024 08h30 HE
|
Real Brands Inc.
North Providence, RI, May 07, 2024 (GLOBE NEWSWIRE) -- Real Brands Inc. (OTCPK: RLBD) announced today that it has added Richard J. Goldberg, MD, MS, to its Board of Directors, and The Company has...
PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
03 mai 2024 11h00 HE
|
PharmAla Biotech
PharmAla launches new educational resource for prescribers of MDMA through the Special Access Program
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
24 avr. 2024 07h00 HE
|
atai Life Sciences
The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression.Initial results from the recently...
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
23 avr. 2024 08h18 HE
|
Optimi Health Corp.
Optimi Health announces innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre.
PharmAla Closes Private Placement and Concurrent Debt Settlement
19 avr. 2024 08h35 HE
|
PharmAla Biotech
PharmAla completes private placement and concurrent debt settlement with Advisor.
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
17 avr. 2024 07h00 HE
|
atai Life Sciences
BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally.BPL-003 was shown to be safe and well-tolerated with a predictable...